Información de la revista
Vol. 35. Núm. S1.
Jornada Post Midyear 2009. “Apostando por el 2020”
Páginas 13-20 (Febrero 2011)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 35. Núm. S1.
Jornada Post Midyear 2009. “Apostando por el 2020”
Páginas 13-20 (Febrero 2011)
Acceso a texto completo
Línea estratégica 2, Medicina basada en la evidencia
Visitas
4067
E.. López-Suñéa
a Servicio de Farmacia, Hospital Clínic, Barcelona, España
Este artículo ha recibido
Información del artículo
El Texto completo está disponible en PDF
Bibliograf¿a
[1]
Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans. J. Clin. Pharmacol. 2010; 50:126-42.
[2]
Limitations of current therapies to prevent thrombosis: a need for novel strategies. Mol Biosyst. 2010; 6:305-15.
[3]
Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, doubleblind OCLA (Omeprazole CLopidogrel Aspirin) study. J. Am. Coll. Cardiol. 2008; 51:256-60.
[4]
Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. Thromb Haemost. 2009; 101:714-9.
[5]
A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ. 2009; 180:713-8.
[6]
Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA. 2009; 301:937-44.
[7]
Proton Pump Inhibitors Effect on Clopidogrel Effectiveness: The Clopidogrel Medco Outcomes Study [abstract 3998]. Circulation. 2008; 118:S815.
[8]
Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a protonpump inhibitor: an analysis of two randomised trials. Lancet. 2009; 374:989-97.
[9]
Baseline Proton Pump Inhibitor Use is Associated with Increased Cardiovascular Events With and Without the Use of Clopidogrel in the CREDO Trial [abstract 3999]. Circulation. 2008; 118:S815.
[10]
Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med. 2010; 363:1909-17.
[11]
Open database: Clinicaltrials.gov [Base de datos en Internet]. Cogentus Pharmaceuticals. Clopidogrel and the optimization of gastrointestinal events (COGENT-1). [citado 01-02-2011]. Disponible en: http://www.clinicaltrials.gov.
[12]
Prophylactic antibiotics cannot reduce infected pancreatic necrosis and mortality in acute necrotizing pancreatitis: evidence from a meta-analysis of randomized controlled trials. Am J Gastroenterol. 2008; 103:104-10.
[13]
Antibiotics prophylaxis in acute necrotizing pancreatitis: an update. Am J Gastroenterol. 2010; 105:705-7.
[14]
American Heart Association Stroke Council. Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator: a science advisory from the American Heart Association/American Stroke Association. Stroke. 2009; 40:2945-8.
[15]
Product Information. Teva Neuroscience, 2010 [consultado 29 Mar 2010]. Disponible en: http://www.azilect.com.
[16]
Product Information. Food and Drug Administration (FDA), 2009 [consultado 29 Mar 2010]. Disponible en: http://www.accessdata.fda.gov/.
[17]
Chen JJ, Adar L, Goren T, Nissim S, Yoni W. A clinical pharmacology study to determine the selective and non-selective doses of rasagiline, a monoamine oxidase type B inhibitor; [Poster 4-092] 44th ASHP Midyear Clinical Meeting Des 6-10, Las Vegas [consultado 29 Mar 2010]. Disponible en: www.cmcgc.com/media/handouts.
[18]
On tyramine, food, beverages and the reversible MAO inhibitor moclobemide. J. Neural Transm Suppl. 1988; 26:31-56.
[19]
Teva Pharma. Ficha técnica del producto, 2009.
[20]
Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial. JAMA. 2008; 299:185-93.
[21]
A randomized, double-blind, placebo-controlled trial of metformin treatment of weight gain associated with initiation of atypical antipsychotic therapy in children and adolescents. Am J Psychiatry. 2006; 163:2072-9.
[22]
Intensive insulin therapy in the critically ill patients. N Engl J Med. 2001; 345:1359-67.
[23]
Benefits and risks of tight glucose control in critically ill adults: a meta-analysis. JAMA. 2008; 300:933-44.
[24]
Intensive versus conventional glucose control in critically ill patients. N Engl J Med. 2009; 360:1283-97.
[25]
Limits to lipid in the literature and lab: what we know, what we don’t know. Anesth Analg. 2009; 108:1062-4.
[26]
Weinberg G. Lipid rescue [consultado 29 Mar 2010]. Disponible en: www.lipidrescue.org/.
[27]
Prevalence and risk factors for development of delirium in surgical and trauma intensive care unit patients. J Trauma. 2008; 65:34-41.
[28]
Delirium as a predictor of mortality in mechanically ventilated patients in the intensive care unit. JAMA. 2004; 291:1753-62.
[29]
The association between delirium and cognitive decline: a review of the empirical literature. Neuropsychol Rev. 2004; 14:87-98.
[30]
Multidisciplinary management of sedation and analgesia in critical care. Semin Respir Crit Care Med. 2001; 22:211-6.
[31]
Benzodiazepine and opioid use and the duration of intensive care unit delirium in an older population. Crit Care Med. 2009; 37:177-83.
[32]
Lorazepam is an independent risk factor for transitioning to delirium in intensive care unit patients. Anesthesiology. 2006; 104:21-6.
[33]
A multicomponent intervention to prevent delirium in hospitalized older patients. N Engl J Med. 1999; 340:669-76.
[34]
Delirium and sedation in the intensive care unit: survey of behaviors and attitudes of 1384 healthcare professionals. Crit Care Med. 2009; 37:825-32.
[35]
Confusion assessment method for diagnosing delirium in ICU patients (CAM-ICU): Cultural adaptation and validation of the Spanish version. Med Intensiva. 2010; 34:4-13.
[36]
Versión en español del método para la evaluación de la confusión en cuidados intensivos, estudio piloto de validación. Med Intensiva. 2010; 34:14-21.
[37]
Efficacy and safety of quetiapine in critically ill patients with delirium: a prospective, multicenter, randomized, double-blind, placebo-controlled pilot study. Crit Care Med. 2010; 38:419-27.
[38]
Olanzapine vs haloperidol: treating delirium in a critical care setting. Intensive Care Med. 2004; 30:444-9.
[39]
A double-blind trial of risperidone and haloperidol for the treatment of delirium. Psychosomatics. 2004; 45:297-301.
[40]
Feasibility, efficacy, and safety of antipsychotics for intensive care unit delirium: the MIND randomized, placebo-controlled trial. Crit Care Med. 2010; 38:428-37.
[41]
Dexmedetomidine vs midazolam for sedation of critically ill patients: a randomized trial. JAMA. 2009; 301:489-99.
[42]
Dexmedetomidine vs. haloperidol in delirious, agitated, intubated patients: a randomised open-label trial. Crit Care. 2009; 13:R75.
[43]
Dexmedetomidine infusion as adjunctive therapy to benzodiazepines for acute alcohol withdrawal. Ann Pharmacother. 2008; 42:1703-5.
Idiomas
Farmacia Hospitalaria
Opciones de artículo
Herramientas
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

es en
Política de cookies Cookies policy
Utilizamos cookies propias y de terceros para mejorar nuestros servicios y mostrarle publicidad relacionada con sus preferencias mediante el análisis de sus hábitos de navegación. Si continua navegando, consideramos que acepta su uso. Puede cambiar la configuración u obtener más información aquí. To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here.